These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. Powell DJ; Rosenberg SA J Immunother; 2004; 27(1):36-47. PubMed ID: 14676632 [TBL] [Abstract][Full Text] [Related]
10. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294 [TBL] [Abstract][Full Text] [Related]
11. Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes. Hu HM; Dols A; Meijer SL; Floyd K; Walker E; Urba WJ; Fox BA J Immunother; 2004; 27(1):48-59. PubMed ID: 14676633 [TBL] [Abstract][Full Text] [Related]
12. Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization. Walker EB; Haley D; Petrausch U; Floyd K; Miller W; Sanjuan N; Alvord G; Fox BA; Urba WJ Clin Cancer Res; 2008 Aug; 14(16):5270-83. PubMed ID: 18698047 [TBL] [Abstract][Full Text] [Related]
13. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Schaefer C; Butterfield LH; Lee S; Kim GG; Visus C; Albers A; Kirkwood JM; Whiteside TL Int J Cancer; 2012 Aug; 131(4):874-84. PubMed ID: 22021080 [TBL] [Abstract][Full Text] [Related]
14. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. Clay TM; Custer MC; McKee MD; Parkhurst M; Robbins PF; Kerstann K; Wunderlich J; Rosenberg SA; Nishimura MI J Immunol; 1999 Feb; 162(3):1749-55. PubMed ID: 9973438 [TBL] [Abstract][Full Text] [Related]
15. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. Phan GQ; Touloukian CE; Yang JC; Restifo NP; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; White DE; Rosenberg SA J Immunother; 2003; 26(4):349-56. PubMed ID: 12843797 [TBL] [Abstract][Full Text] [Related]
16. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Salgaller ML; Marincola FM; Cormier JN; Rosenberg SA Cancer Res; 1996 Oct; 56(20):4749-57. PubMed ID: 8840994 [TBL] [Abstract][Full Text] [Related]
17. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients. Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350 [TBL] [Abstract][Full Text] [Related]
18. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
19. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Ginsberg BA; Gallardo HF; Rasalan TS; Adamow M; Mu Z; Tandon S; Bewkes BB; Roman RA; Chapman PB; Schwartz GK; Carvajal RD; Panageas KS; Terzulli SL; Houghton AN; Yuan JD; Wolchok JD Clin Cancer Res; 2010 Aug; 16(15):4057-65. PubMed ID: 20647477 [TBL] [Abstract][Full Text] [Related]
20. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. Yang S; Linette GP; Longerich S; Haluska FG J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]